Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) from a hold rating to a sell rating in a research report released on Monday, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Other equities analysts have also issued reports about the company. LADENBURG THALM/SH SH reiterated a buy rating and issued a $9.00 price objective on shares of Armata Pharmaceuticals in a research report on Monday, July 15th. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.

Shares of ARMP opened at $4.65 on Monday. Armata Pharmaceuticals has a 52-week low of $2.10 and a 52-week high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.40).

An institutional investor recently bought a new position in Armata Pharmaceuticals stock. BlackRock Inc. bought a new position in shares of Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,264 shares of the company’s stock, valued at approximately $45,000. BlackRock Inc. owned about 0.47% of Armata Pharmaceuticals at the end of the most recent quarter.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Featured Story: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.